LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

Начало・Списък с акции・Novo Nordisk A-S

Novo Nordisk A-S

Затворен

Сектор Здравеопазване

131.05 0.18

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

130.75

Максимум

131.39

Ключови измерители
By Trading Economics
Приходи	-5.4B 20B
Продажби	2.7B 68B
P/E Средно за сектора	49.94 103.001
EPS	4.49
Марж на печалбата	29.459
EBITDA	-1.2B 36B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+10.38 upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	711M 471B
Предишно отваряне	130.87
Предишно затваряне	131.05

Настроения в новините

By Acuity

86%

14%

331 / 365 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

130.53 / 134.62 Подкрепа & съпротива

Novo Nordisk A-S Графика

Свързани новини

7.08.2024 г., 10:13 ч. UTC

Печалби

Novo Nordisk's Wegovy Sales Disappoint -- 2nd Update

7.08.2024 г., 06:58 ч. UTC

Печалби

Wegovy Maker Novo Nordisk Lifts Sales Guidance as Weight-Loss Drug Demand Continues to Surge -- Update

7.08.2024 г., 06:10 ч. UTC

Печалби

Wegovy Maker Novo Nordisk Lifts Sales Guidance as Weight-Loss Drug Demand Continues to Surge

3.09.2024 г., 11:09 ч. UTC

Топ новини

Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly. -- Barrons.com

27.08.2024 г., 05:30 ч. UTC

Топ новини

Weight-Loss Drugs Get More Good News. For Investors, It's Still Too Soon to Celebrate. -- Barrons.com

14.08.2024 г., 12:01 ч. UTC

Пазарно говорене

Печалби

Novo Nordisk's Pricing and Pipeline to Remain Hot Topics -- Market Talk

9.08.2024 г., 11:30 ч. UTC

Топ новини

Eli Lilly Is Gaining on Novo Nordisk in the Obesity Race -- Heard on the Street -- WSJ

9.08.2024 г., 07:30 ч. UTC

Пазарно говорене

Novo Nordisk Share Pullback Represents Great Opportunity -- Market Talk

8.08.2024 г., 15:44 ч. UTC

Топ новини

Печалби

Eli Lilly Shows We Haven't Hit Peak Obesity Yet -- WSJ

8.08.2024 г., 11:36 ч. UTC

Пазарно говорене

Печалби

Novo Nordisk's Share-Price Weakness Provides an Opportunity -- Market Talk

8.08.2024 г., 07:16 ч. UTC

Пазарно говорене

Печалби

Novo Nordisk's Share-Price Drop Provides Buying Opportunity -- Market Talk

7.08.2024 г., 20:30 ч. UTC

Топ новини

Eli Lilly Reports Earnings Thursday Amid a Stock Slump. Here's What to Expect. -- Barrons.com

7.08.2024 г., 16:39 ч. UTC

Печалби

Novo Nordisk's Wegovy Sales Disappoint -- Update

7.08.2024 г., 15:30 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Novo Nordisk's Wegovy Sales Disappoint -- WSJ

7.08.2024 г., 14:22 ч. UTC

Топ новини

Печалби

It Isn't Time to Worry About Wegovy Yet -- Heard on the Street -- WSJ

7.08.2024 г., 12:28 ч. UTC

Пазарно говорене

Печалби

Novo Nordisk's Core Products Disappoint -- Market Talk

7.08.2024 г., 12:04 ч. UTC

Печалби

Novo Nordisk Execs Were Speaking on a Call After 2Q Earnings

7.08.2024 г., 11:34 ч. UTC

Печалби

Novo Nordisk US Head: As Wegovy Volumes Go Up, Prices Will Come Down

7.08.2024 г., 11:34 ч. UTC

Печалби

Novo Nordisk CEO: When You Move Into New Sales Channels it Comes With a Discount

7.08.2024 г., 11:34 ч. UTC

Печалби

Novo Nordisk CEO: Wegovy Now Covered in 20 States Through Medicaid

7.08.2024 г., 11:05 ч. UTC

Пазарно говорене

Печалби

Novo Nordisk Delivers Messy Quarter as Wegovy Misses The Mark -- Market Talk

7.08.2024 г., 10:55 ч. UTC

Печалби

Stock Market Madness Highlights This Problem for -2-

7.08.2024 г., 10:55 ч. UTC

Печалби

Stock Market Madness Highlights This Problem for Novo Nordisk and Super Micro. And 5 Other Things to Know Today. -- Barrons.com

7.08.2024 г., 09:07 ч. UTC

Печалби

Горещи акции

Stocks to Watch Wednesday: Super Micro, Rivian, Airbnb -- WSJ

7.08.2024 г., 08:55 ч. UTC

Топ новини

These Stocks Are Moving the Most Today: Super Micro, Lumen, Airbnb, Rivian, Fortinet, Upstart, Disney, and More -- Barrons.com

7.08.2024 г., 07:32 ч. UTC

Пазарно говорене

Печалби

Novo Nordisk Wegovy Sales Disappoint -- Market Talk

7.08.2024 г., 05:45 ч. UTC

Печалби

Novo Nordisk Declares Interim Dividend of DKK3.50

7.08.2024 г., 05:44 ч. UTC

Печалби

Novo Nordisk 2Q Gross Margin 84.9% Vs 85.5%, Op Margin 38.1% Vs 44.0%

7.08.2024 г., 05:40 ч. UTC

Печалби

Novo Nordisk 2Q Wegovy Drug Sales DKK11.66B Vs DKK7.52B

7.08.2024 г., 05:38 ч. UTC

Печалби

Novo Nordisk: Sales Growth Has Resulted in Periodic Supply Constraints, Related Drug Shortage Notifications

Сравнение с други в отрасъла

Ценова промяна

Novo Nordisk A-S Прогноза

Ценова цел

By TipRanks

10.38% нагоре

12-месечна прогноза

Среден 144.75 USD 10.38%

Висок 166 USD

Нисък 82.5 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Novo Nordisk A-S през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

9 ratings

Купи

Задържане

Продай

Според 9 анализатори, дали борсови рейтинги на Novo Nordisk A-S през последните 3 месеца.

Техническа оценка

By Trading Central

130.53 / 134.62Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bullish event.

Настроение

By Acuity

331 / 365 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

EBITDA

Оперативна печалба

Относно Novo Nordisk A-S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.